Contact Us Today|info@empharmd.com

Diltiazem IV to PO Explained

One of the oldest posts on EMPharmD has finally received an update. One of the most prominent lessons I've learned since graduating residency years ago is that the more I learn, the more I realize I do not know, and seeking out help is not a sign of weakness, but a strength.  Artist rendering of diltiazem formula investigationAs such, when I encountered a wall in trying to trace the origin of the diltiazem IV to PO [...]

By |2016-06-05T17:50:00-05:00June 5th, 2016|EM PharmD Blog|0 Comments

Trick of the Trade: Simplify Treatment of the SSTI

In 2010, skin and soft tissue infections (SSTIs) accounted for approximately 4.2 million emergency department visits (1). With such a bread-and-butter emergency medicine encounter, one might not give a second thought as to whether the standard dosing is less than ideal. However, the nuance of appropriate pharmacokinetic dosing that drug references omit may be the more ideal approach. The most appropriate dosing regimen, based on pharmacokinetic parameters, may not be highlighted by tertiary drug resources [...]

By |2016-05-25T09:30:00-05:00May 25th, 2016|EM PharmD Blog|0 Comments

Euglycemic DKA from SGLT2 Inhibitors: Don’t Worry, I Can’t Pronounce Them Either

Diabetic ketoacidosis in patients with presenting serum blood glucose less than 200 is not common. Particularly when practicing in the Bible/Diabetes belt of the United States. This euglycemic DKA (euDKA) is more often associated in patients with type 1 diabetes in conjunction with starvation and acute illness.[1] It's difficult to determine an incidence of euglycemic serum glucose among all DKA cases in the literature given the migration of the serum glucose cutoff from 300 or less [...]

By |2016-05-04T18:54:00-05:00May 4th, 2016|EM PharmD Blog|0 Comments

Euglycemic DKA from SGLT2 Inhibitors: Don't Worry, I Can't Pronounce Them Either

Diabetic ketoacidosis in patients with presenting serum blood glucose less than 200 is not common. Particularly when practicing in the Bible/Diabetes belt of the United States. This euglycemic DKA (euDKA) is more often associated in patients with type 1 diabetes in conjunction with starvation and acute illness.[1] It's difficult to determine an incidence of euglycemic serum glucose among all DKA cases in the literature given the migration of the serum glucose cutoff from 300 or less [...]

By |2016-05-04T18:54:00-05:00May 4th, 2016|EM PharmD Blog|0 Comments

Long-Term Functional Outcomes of Warfarin-Induced Coagulopathy Following Prothrombin Complex Concentrate and Fresh Frozen Plasma

Vitamin K antagonist therapy such as warfarin has been demonstrated to decrease the incidence of stroke by approximately sixty percent in patients with atrial fibrillation (1). Unfortunately, warfarin is an agent with a narrow therapeutic index that is sensitive to drug-drug interactions, changes in diet and overall patient compliance. The incidence of warfarin-induced hemorrhage can be life-threatening and often requires emergent reversal. Historically, fresh frozen plasma (FFP) has been utilized to reverse the effects of [...]

By |2016-04-25T10:00:00-05:00April 25th, 2016|EM PharmD Blog|0 Comments

8 Points Worth Noting From New Guideline for Convulsive Status Epilepticus

In the January/February issue of Epilepsy Currents, the American Epilepsy Society put forth a guideline on the management of convulsive status epilepticus (CSE) in adult and pediatric patients (1).While I do appreciate the efforts put forth by the authors who reviewed the available evidence related to CSE, some points from the guideline are worth addressing and further consideration. This is not an all-inclusive list by any means, but the points detailed below are those that [...]

By |2016-03-08T11:00:00-05:00March 8th, 2016|EM PharmD Blog|0 Comments

Weighing In On Alteplase Dosing: Is Estimating Weight Harming Our Patients?

When a stroke victim rolls into the emergency department (ED) we know we have a limited time window to administer alteplase (recombinant tissue-type plasminogen activator [r-tPA]). The pressure of this narrow therapeutic window often pressures hospital staff to administer the potentially brain-saving medication as early as possible. Often, administration is hastened by estimating patient weight as a basis for calculating the critical 0.9 mg/kg weight-based dose. However, the question remains if we are appropriately estimating [...]

By |2016-02-24T20:10:00-05:00February 24th, 2016|EM PharmD Blog|0 Comments

Gabapentin Misuse: A Growing Challenge

With the opioid abuse epidemic that we clinicians in the emergency department encounter as part of our daily practice, the movement towards the use of alternative agents continues to evolve for the management of pain in our patients. In taking advantage of traditional and novel mechanisms of action of these agents, acute pain in patients in the emergency department may be managed appropriately without posing the risk of introducing opioid-naive patients to opioids or worse, [...]

By |2016-02-11T11:00:00-05:00February 11th, 2016|EM PharmD Blog|0 Comments

Managing Rate Control in the Face of Borderline Hypotension

Encountering patients in afib with RVR is a daily occurrence in the emergency department. Rate control with AV blocking drugs are standard approaches for stable patients and good ol’ electricity for those who are unstable. But there is a group in-between that presents a different challenge. Those who are in afib but are relatively hypotensive, by which I mean SBPs in the 90’s or low 100’s. In these patients, pharmacologic rate control may improve SBPs [...]

By |2016-02-03T17:00:00-05:00February 3rd, 2016|EM PharmD Blog|0 Comments

Trick of the Trade: Diphenhydramine for Local Anesthesia

Say you have any one of the following three scenarios in a patient who requires local anesthesia for repairing a minor wound laceration in the emergency department: 1 – Documented allergy to “-caine” agents (now, before you grumble…the patient assures you that this is a true allergy; yes, the whole nine yards with full-blown anaphylaxis that occurred years ago with some “-caine”). 2 – Shortage of all forms of parenteral lidocaine 1% and 2% (not [...]

By |2016-01-27T11:00:00-05:00January 27th, 2016|EM PharmD Blog|0 Comments